Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.57 |
| ▸ | PGK1 | P00558 | 3/20 | 0.36 |
| ▸ | PGK2 | P07205 | 3/20 | 0.36 |
| ▸ | PNP | P00491 | 6/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743575 | 0.78 | LPAR1 (0.59) | LPAR1LPAR3PGK1PGK2PNP | |
| SCHEMBL1533877 | 0.76 | LPAR1 (0.83) | LPAR1LPAR3FDPSGGPS1 | |
| SCHEMBL6154737 | 0.76 | LPAR1 (0.34) | LPAR1LPAR3 | |
| SCHEMBL1533943 | 0.74 | LPAR1 (0.96) | LPAR1LPAR3FDPSGGPS1 | |
| SCHEMBL9109027 | 0.74 | LPAR1 (0.61) | LPAR1LPAR3PGK1PGK2PNP | |
| SCHEMBL193245 | 0.73 | LPAR1 (1.00) | LPAR1LPAR3FDPSGGPS1 | |
| SCHEMBL9110451 | 0.73 | LPAR1 (0.64) | LPAR1LPAR3PGK1PGK2PNP | |
| SCHEMBL18720921 | 0.73 | LPAR1 (0.59) | LPAR1LPAR3PGK1PGK2FDPS | |
| SCHEMBL160868 | 0.70 | LPAR1 (0.68) | LPAR1LPAR3FDPSGGPS1 | |
| SCHEMBL15022714 | 0.70 | FDPS (0.54) | LPAR1LPAR3PGK1PGK2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | LPAR1 1509/4885LPAR3 1919/4885PGK1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.